A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
Globally some 1.8 million children and young people (CYP) live with type 1 diabetes (T1D) and in low-and middle-income countries (LMICs) prevalence of the disease is on the rise. In…
Localising the production of medicines has become a core priority for the Saudi government over the past decade as it attempts to increase national health security, create highly skilled jobs,…
With Saudi Arabia striving to position itself as a regional leader in biopharmaceutical R&D by 2030 and to cement itself as a global hub before 2040, there has been a…
Saudi Arabia has long represented an alluring marketplace for the global MedTech industry. Not only does the Kingdom constitute the largest spender on healthcare across the Middle East and North…
With increased average disposable income in Saudi Arabia eliciting more sedentary lifestyles and less healthy dietary choices, more than 68 percent of all mortality in the Kingdom is nowadays attributed…
When it was first initiated back in 2016, in the wake of the launch of Vision 2030, few industry insiders could have anticipated just quite how radical Saudi Arabia’s Health…
Saudi Arabia’s pharmaceuticals market grew an impressive 9.1 percent in 2024 underscoring its position as the regional heavyweight, and projecting a sales value of around USD 11.6 billion, which constitutes…
Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’…
In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
2023 may have been a breakthrough year for cell and gene therapies with the FDA approving a record of seven novel treatments, but 2024 did not fall behind in the…
See our Cookie Privacy Policy Here
